Analyst Sam Eiber of BTIG reiterated a Buy rating on Establishment Labs Holdings (ESTA – Research Report), retaining the price target of $62.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sam Eiber has given his Buy rating due to a combination of factors including the strong performance and growth potential of Establishment Labs Holdings. The company has reiterated its positive outlook for 2025, with significant revenue growth expected in the U.S. market, particularly from its Motiva implants. The consistent increase in monthly order trends and the positive feedback from U.S. surgeons, who are early adopters of Motiva, highlight the product’s stable results and patient preference.
Furthermore, the company’s strategic initiatives, such as the upcoming launch of the Preservé procedure and the expansion of minimally invasive tools, are expected to drive future growth. With plans to file for a reconstruction indication with the FDA and the potential of new opportunities like GLP-1s, Establishment Labs is poised for continued expansion. The management’s expectation of at least 20% sales growth over the next three years and the anticipation of becoming cash flow positive by 2026 further support the Buy rating.